CHARLESTON, S.C., Aug. 18, 2010 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB:RMCP), announces detailed studies to further expand the value of its proprietary MRI imaging tools.
These studies led by Professor of Anatomy H. Keith Brown, PhD, address very large and important markets.
The first study will assess hemorrhagic age. This is very critical in assessing the proper treatment for head injuries. Traumatic brain injury (TBI) is a serious public health problem in the United States. Each year, traumatic brain injuries contribute to a substantial number of deaths and cases of permanent disability. Recent data shows that, on average, approximately 1.7 million people sustain a traumatic brain injury annually. By being able to quickly assess the "age" of a hemorrhage, we can assess the extent of the injury and choose the most appropriate treatment quickly. This has the potential to deliver improved patient outcome and improved economics.
The second study will allow for tissue characterization. This is important in assessing what tissue has been damaged by cancer and what tissue has improved by the cancer treatment protocol. This allows the medical team to alter treatments so that better outcomes are achieved quickly and at less cost. Knowing which drugs are working better in both treatment and clinical trial situations will potentially have substantial economic benefits. Every day, over 100 adults will be diagnosed with a primary brain tumor (starting in the brain), and many more will be diagnosed with a cancer that has spread to the brain from someplace else in the body, such as the lung or breast. Additionally, thousands of children get diagnosed every year with a brain tumor. Once diagnosed, speed in finding the most effective treatment is often critical in determining patient outcomes.
Tom O'Brien, President of Revolutions Medical and an early pioneer in the launch of Magnetic Resonance with Johnson & Johnson's Technicare Corporation states, "30 years ago the founders and Nobel Prize winners envisioned applications of Magnetic Resonance in color where the diagnosis could be made and success of treatment could be monitored. With these first application studies we will hopefully realize that dream of the MRI founders. Future applications may be possible where we can follow hemorrhage history through clear indications as well as assess effectiveness of cancer treatments more easily through changes in color."
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.
For additional information, please visit Revolutions Medical corporate website: http://www.revolutionsmedical.com
Investor Resource Center
Fact Sheet:
http://content.stockpr.com/rmcp/files/RMCP+-+Fact+Sheet+02-26-10.pdf
CEO Ron Wheet Audio Interview:
http://ir.stockpr.com/revolutionsmedical/media-center/view/33/
RevVac Demo Video:
http://revolutionsmedical.com/
To be added to the Revolutions Medical investor email list, please email Skey@revolutionsmedical.com with RMCP in the subject line.
Become a RevMed fan and follow the Company on Facebook - visit http://www.Facebook.com/Revmed
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.